FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

BioLexis Pte Ltd.
2. Issuer Name and Ticker or Trading Symbol

Outlook Therapeutics, Inc. [ OTLK ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

36 ROBINSON ROAD, #13-01 CITY HOUSE
3. Date of Earliest Transaction (MM/DD/YYYY)

1/27/2020
(Street)

SINGAPORE, U0 068877
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 1/29/2020  M  4657852 A$0.232 21606437 D (1)(2) 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Warrant (Right to Buy) $7.20 (3)1/27/2020  D (4)    2093750 (3)  (5)10/31/2025 Common Stock 2093750 $0.00 (6)0 D (1)(2) 
Warrant (Right to Buy) $0.232 1/27/2020  A (4)  2093750     (5)10/31/2025 Common Stock 2039750 $0.00 (6)2039750 D (1)(2) 
Warrant (Right to Buy) $7.80 (3)1/27/2020  D (7)    1282051 (3)  (5)5/14/2026 Common Stock 1282051 $1.00 (3)0 D (1)(2) 
Warrant (Right to Buy) $0.232 1/27/2020  A (7)  1282051     (5)5/14/2026 Common Stock 1282051 $1.00 (3)1282051 D (1)(2) 
Warrant (Right to Buy) $7.80 (3)1/27/2020  D (8)    1282051 (3)  (5)6/8/2026 Common Stock 1282051 $1.00 (3)0 D (1)(2) 
Warrant (Right to Buy) $0.232 1/27/2020  A (8)  1282051     (5)6/8/2026 Common Stock 1282051 $1.00 (3)1282051 D (1)(2) 
Warrant (Right to Buy) $0.232 1/29/2020  M     2093750   (5)10/31/2025 Common Stock 2093750 $0.00 (6)0 D (1)(2) 
Warrant (Right to Buy) $0.232 1/29/2020  M     1282051   (5)5/14/2026 Common Stock 1282051 $1.00 0 D (1)(2) 
Warrant (Right to Buy) $0.232 1/29/2020  M     1282051   (5)6/8/2026 Common Stock 1282051 $1.00 0 D (1)(2) 

Explanation of Responses:
(1) These securities are held of record by BioLexis Pte Ltd. ("BioLexis"). Tenshi Life Sciences Private Limited ("Tenshi"), a private investment vehicle controlled by Arun Kumar Pillai ("Kumar"), and GMS Pharma (Singapore) Pte. Limited ("GMS Pharma"), a private investment company and wholly-owned subsidiary of GMS Holdings, are the 50:50 beneficial owners of BioLexis, in which each of Tenshi and GMS Pharma owns 50% of the outstanding voting shares. Kumar, a natural person, is the holder of a controlling interest in Tenshi. Ghiath M. Sukhtian ("Ghiath Sukhtian"), a natural person, is the holder of a controlling interest in GMS Holdings, which is the holder of a controlling interest in GMS Pharma.
(2) By virtue of the relationships described above in Footnote 1, Kumar and Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by BioLexis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. BioLexis has designated four representatives to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
(3) Reflects the 1:8 reverse stock split effected by the Issuer on March 15, 2019.
(4) The two reported transactions involved an amendment of an outstanding Warrant, resulting in the deemed cancellation of the "old" Warrant and the issuance of a replacement Warrant. The Warrant was originally issued on October 31, 2017.
(5) Immediately exercisable.
(6) This Warrant was issued to BioLexis in consideration of its purchase of Series A Preferred Stock pursuant to that certain Purchase Agreement dated October 31, 2017.
(7) The two reported transactions involved an amendment of an outstanding Warrant, resulting in the deemed cancellation of the "old" Warrant and the issuance of a replacement Warrant. The Warrant was originally issued on May 14, 2018.
(8) The two reported transactions involved an amendment of an outstanding Warrant, resulting in the deemed cancellation of the "old" Warrant and the issuance of a replacement Warrant. The Warrant was originally issued on June 8, 2018.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
BioLexis Pte Ltd.
36 ROBINSON ROAD
#13-01 CITY HOUSE
SINGAPORE, U0 068877
XX

Pillai Arun Kumar
#30, 1ST MAIN
J.P. NAGAR 3RD PHASE
BANGALORE, K7 560078
XX

Sukhtian Ghiath M.
7TH CIRCLE, ZAHRAN STREET
ZAHRAN PLAZA BLDG, 4TH FLOOR
AMMAN, M2 11844
XX


Signatures
/s/ BioLexis Pte. Ltd., By: Lawrence Kenyon, Attorney-in-Fact1/29/2020
**Signature of Reporting PersonDate

/s/ Lawrence Kenyon, Attorney-in-Fact1/29/2020
**Signature of Reporting PersonDate

/s/ Lawrence Kenyon, Attorney-in-Fact1/29/2020
**Signature of Reporting PersonDate

Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Outlook Therapeutics Charts.
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Outlook Therapeutics Charts.